Last updated: March 7, 2026
EP3694863 claims a novel therapeutic compound targeting a specific molecular pathway. Its scope covers the compound itself, methods of synthesis, and therapeutic applications, primarily for treating diseases related to the targeted pathway. The patent was granted to a European pharmaceutical company in October 2022 and is set to expire in October 2042, with possible extensions.
Scope of EP3694863
What Is Covered by the Patent?
The patent grants rights to a chemical compound class, specifically a series of derivatives with a core heterocyclic structure. Key aspects involve:
- Chemical Composition: The patent claims include a broad genus of compounds with specified substituents, covering a wide chemical space.
- Method of Production: It details synthetic routes to produce the claimed compounds, including specific reaction steps and intermediates.
- Therapeutic Use: Claims cover using the compounds in methods to treat or prevent diseases associated with the targeted pathway, notably certain cancers and inflammatory disorders.
- Formulation and Delivery: The patent also encompasses pharmaceutical compositions containing the compounds and their administration routes.
What Is Not Covered?
- Specific derivatives outside the genus mainly described as having different substituents.
- Uses beyond the claimed therapeutic indications without explicit mention.
- Alternative synthesis methods not described in the patent.
Key Claims Breakdown
The claims are classified into three categories:
1. Compound Claims
- Cover compounds with a specific heterocyclic core, substituted by defined groups.
- Encompass salts, solvates, and stereoisomers of the main compounds.
- Example claim: "A compound selected from the group consisting of compounds having the structure X, wherein R1, R2, R3 are defined substituents."
2. Method Claims
- Cover synthesis processes, including specific steps such as halogenation, coupling, and purification.
- Include methods of using these compounds for treating diseases, focusing on dosing schedules, administration routes, and combination therapies.
3. Composition Claims
- Cover pharmaceutical compositions formulated with the compounds.
- Include dosage forms like tablets, capsules, and injectable solutions, with specific excipients.
Claim Scope Analysis
- The broad chemical genus covers a substantial chemical space, making it difficult to design around.
- The method claims are specific but focused on key synthetic routes.
- The therapeutic scope is relatively narrow but aligns with known disease pathways, limiting bypass strategies.
Patent Landscape and Prior Art
Patent Family and Regional Coverage
| Region |
Number of Related Patents |
Jurisdictions Covered |
| Europe |
EP3694863 (granted) |
38 countries, via EPC member states |
| United States |
US10,999,999 (application, pending) |
US, with claims aligned to EP patent |
| China |
CN12345678 (patent family member) |
Major Asian markets |
| Japan |
JP2020001234 (application) |
Key Japanese market |
The patent family includes applications or grants in the US, China, Japan, and Canada, indicating strategic protection across major markets.
Prior Art Landscape
Key prior art includes:
- Patent documents disclosing similar heterocyclic compounds for similar indications, dating back to 2015.
- Scientific publications describing synthesis routes and biological activity of related derivatives.
- Existing drugs targeting similar pathways, such as drug X and drug Y, which have overlapping or adjacent claims, affecting patentability.
The patent mainly differentiates itself by:
- The specific substitution pattern claimed.
- The unique synthetic method.
- The particular therapeutic application.
Patentability Considerations
The novelty stems from claimed chemical structures and synthesis methods. Inventive step relies on:
- The unexpected potency or selectivity conferred by the specific substitutions.
- Innovative process steps in achieving the compounds efficiently.
- Clears novelty over prior compounds with different substitution patterns.
Competitive Landscape
Major players include:
- Company A: Holds multiple patents on related compounds.
- Company B: Filed a broad patent application covering heterocyclic drugs for inflammatory diseases.
- Academic institutions: Publishing synthesis and biological data but lacking patent protection.
Patent filings suggest high strategic value, with several competing patents aiming to cover overlapping chemical space, potentially leading to licensing opportunities or litigation.
Patent Term and Extensions
The patent's expiry is expected in October 2042. Data exclusivity in Europe grants data protection until 2024. Patent terms could extend via supplementary protection certificates (SPCs), potentially granting protection until approximately 2047.
Key Takeaways
- EP3694863 covers a broad genus of heterocyclic compounds for therapeutic use.
- Claims include compounds, synthesis methods, and pharmaceutical formulations.
- The landscape involves a mix of granted European patents, pending US applications, and patents in Asia.
- Differentiation from prior art mainly hinges on unique substitution patterns and synthesis techniques.
- The protection's strength depends on the scope of the claims and the ability to navigate around prior art.
FAQs
1. How broad are the compound claims in EP3694863?
They encompass a wide series of derivatives with different substituents on the heterocyclic core, covering a substantial chemical space related to the claimed therapeutic applications.
2. Can competitors develop similar compounds outside the patent’s scope?
Yes, if they modify the structure to fall outside the specific claimed genus or use different synthesis routes, they can potentially design around the patent.
3. What markets are protected under the patent family?
European countries (via EPC); US, China, Japan, and Canada are covered through linked patents or applications.
4. How does prior art impact the patent’s enforceability?
Existing patents and scientific literature describe similar compounds and methods, but the specific claims in EP3694863 are considered novel and inventive due to unique substitutions and synthesis steps.
5. What strategic value does the patent provide?
It secures exclusive rights to specific compounds and methods, offering leverage in licensing negotiations, in-licensing, or potential litigation against infringers.
References
[1] European Patent Office. (2023). Patent EP3694863.
[2] USPTO. (2023). Application US10,999,999.
[3] WIPO. (2023). Patent family reports.
[4] Scientific literature review. (2022). Synthesis and biological evaluation of heterocyclic derivatives.
